Direxion Daily Semicondct Bull 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

VS TR -1x Short VIX Futures ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Direxion Daily Technology Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X ETF

Guggenheim Solar ETF

Direxion Daily Financial Bull 3X ETF

Bank Of Montreal

ProShares UltraPro Dow30

VS TR 2x Long VIX Futures ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares Ultra VIX Short-Term Futures

ProShares Ultra Bloomberg Natural Gas

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily S&P Biotech Bear 3X ETF

Direxion Technology Bear 3X Shares

Direxion Financial Bear 3X Shar

Direxion Daily Gold Miners Bull 3X ETF

QuantumScape Corporation Class A Common Stock

Oklo Inc.

Reddit Inc. Class A Common Stock

Uber Technologies Inc. Common Stock

Gray Television Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

Carnival Corporation Common Stock

Ciena Corporation Common Stock

Snap Inc. Class A Common Stock

KKR & Co. Inc. Common Stock

FedEx Corporation Common Stock

AgEagle Aerial Systems Inc. Common Stock

Alamos Gold Inc. Class A Common Shares

Occidental Petroleum Corporation Common Stock

Civitas Resources Inc. Common Stock

Gold Fields Limited American Depositary Shares

Noble Corporation plc A Ordinary Shares

Exxon Mobil Corporation Common Stock

United Microelectronics Corporation (NEW) Common Stock

Raytheon Technologies Corporation Common Stock

Click here to get full coverage on Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer - Pharmacy Times

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer  Pharmacy Times

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer - Pharmacy Times

Click here to get full coverage on ALK in cancer: from function to therapeutic targeting - Nature

ALK in cancer: from function to therapeutic targeting  Nature

ALK in cancer: from function to therapeutic targeting - Nature

Click here to get full coverage on ALK and Lung Cancer - American Lung Association

ALK and Lung Cancer  American Lung Association

ALK and Lung Cancer - American Lung Association

Click here to get full coverage on Ten Years of Advances: The Story of an ALK-Positive Lung Cancer Survivor - Yale School of Medicine

Ten Years of Advances: The Story of an ALK-Positive Lung Cancer Survivor  Yale School of Medicine

Ten Years of Advances: The Story of an ALK-Positive Lung Cancer Survivor - Yale School of Medicine

Click here to get full coverage on (ALK) Trading Report - news.stocktradersdaily.com

(ALK) Trading Report  news.stocktradersdaily.com

(ALK) Trading Report - news.stocktradersdaily.com

Click here to get full coverage on Case Report: CAR-T Therapy for Primary Cerebellar ALK-Negative Anaplastic Large Cell Lymphoma - Frontiers

Case Report: CAR-T Therapy for Primary Cerebellar ALK-Negative Anaplastic Large Cell Lymphoma  Frontiers

Case Report: CAR-T Therapy for Primary Cerebellar ALK-Negative Anaplastic Large Cell Lymphoma - Frontiers

Click here to get full coverage on Burnley owners ALK Capital in talks over buying Espanyol stake - The New York Times

Burnley owners ALK Capital in talks over buying Espanyol stake  The New York Times

Burnley owners ALK Capital in talks over buying Espanyol stake - The New York Times

Click here to get full coverage on Advanced test predicts ALK inhibitor success in lung cancer - Drug Target Review

Advanced test predicts ALK inhibitor success in lung cancer  Drug Target Review

Advanced test predicts ALK inhibitor success in lung cancer - Drug Target Review

Click here to get full coverage on Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC - OncLive

Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC  OncLive

Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC - OncLive

Click here to get full coverage on Development of a TBK1 and ALK dual inhibitor for alleviating depressive behavior via anti-inflammatory effects - ScienceDirect.com

Development of a TBK1 and ALK dual inhibitor for alleviating depressive behavior via anti-inflammatory effects  ScienceDirect.com

Development of a TBK1 and ALK dual inhibitor for alleviating depressive behavior via anti-inflammatory effects - ScienceDirect.com

Click here to get full coverage on Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC - CancerNetwork

Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC  CancerNetwork

Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC - CancerNetwork

Click here to get full coverage on Alaska Air Group (ALK) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance

Alaska Air Group (ALK) Suffers a Larger Drop Than the General Market: Key Insights  Yahoo Finance

Alaska Air Group (ALK) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance

Click here to get full coverage on RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer - Nature

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer  Nature

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer - Nature

Click here to get full coverage on Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data - Frontiers

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data  Frontiers

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data - Frontiers

Click here to get full coverage on Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial - Nature

Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial  Nature

Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial - Nature

Click here to get full coverage on Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance - Nature

Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance  Nature

Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance - Nature

Click here to get full coverage on Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study - Nature

Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study  Nature

Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study - Nature

Click here to get full coverage on HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy - Nature

HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy  Nature

HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy - Nature

Click here to get full coverage on Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer - Nature

Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer  Nature

Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer - Nature

Click here to get full coverage on Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer | Cell Death & Disease - Nature

Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer | Cell Death & Disease  Nature

Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer | Cell Death & Disease - Nature

Click here to get full coverage on First Approval for New ALK Inhibitor - American Association for Cancer Research (AACR)

First Approval for New ALK Inhibitor  American Association for Cancer Research (AACR)

First Approval for New ALK Inhibitor - American Association for Cancer Research (AACR)

Click here to get full coverage on Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function - Nature

Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function  Nature

Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function - Nature

Click here to get full coverage on Latest Advances in Management of Advanced NSCLC with ALK or ROS1 Mutations - OncLive

Latest Advances in Management of Advanced NSCLC with ALK or ROS1 Mutations  OncLive

Latest Advances in Management of Advanced NSCLC with ALK or ROS1 Mutations - OncLive

Click here to get full coverage on Alaska Air (ALK) Soars 22.6%: Is Further Upside Left in the Stock? - Yahoo Finance

Alaska Air (ALK) Soars 22.6%: Is Further Upside Left in the Stock?  Yahoo Finance

Alaska Air (ALK) Soars 22.6%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC - CancerNetwork

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC  CancerNetwork

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC - CancerNetwork

Click here to get full coverage on Alaska Air Group (ALK) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance

Alaska Air Group (ALK) Stock Slides as Market Rises: Facts to Know Before You Trade  Yahoo Finance

Alaska Air Group (ALK) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance

Click here to get full coverage on ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025 - Yahoo Finance

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025  Yahoo Finance

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025 - Yahoo Finance

Click here to get full coverage on Successful Late-Line Pralsetinib Treatment in an ALK-Rearranged Lung Adenocarcinoma Patient with KIF5B-RET Fusion Resistant to Alectinib: A Case Study - Frontiers

Successful Late-Line Pralsetinib Treatment in an ALK-Rearranged Lung Adenocarcinoma Patient with KIF5B-RET Fusion Resistant to Alectinib: A Case Study  Frontiers

Successful Late-Line Pralsetinib Treatment in an ALK-Rearranged Lung Adenocarcinoma Patient with KIF5B-RET Fusion Resistant to Alectinib: A Case Study - Frontiers

Click here to get full coverage on ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non–Small Cell Lung Cancer? - ASCO Publications

ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non–Small Cell Lung Cancer?  ASCO Publications

ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non–Small Cell Lung Cancer? - ASCO Publications

Click here to get full coverage on A case of pulmonary ALK-positive histiocytosis combined with Birt-Hogg-Dubé syndrome carrying an EML4::ALK gene fusion: a case report and literature review - Frontiers

A case of pulmonary ALK-positive histiocytosis combined with Birt-Hogg-Dubé syndrome carrying an EML4::ALK gene fusion: a case report and literature review  Frontiers

A case of pulmonary ALK-positive histiocytosis combined with Birt-Hogg-Dubé syndrome carrying an EML4::ALK gene fusion: a case report and literature review - Frontiers

Click here to get full coverage on Novel ALK gene mutation in inflammatory myofibroblastic tumor of the thyroid: a case report - Frontiers

Novel ALK gene mutation in inflammatory myofibroblastic tumor of the thyroid: a case report  Frontiers

Novel ALK gene mutation in inflammatory myofibroblastic tumor of the thyroid: a case report - Frontiers

Click here to get full coverage on Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 - PR Newswire

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025  PR Newswire

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 - PR Newswire

Click here to get full coverage on Alaska Air Group (ALK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

Alaska Air Group (ALK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  Yahoo Finance

Alaska Air Group (ALK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

Click here to get full coverage on Key Differences Among ALK Inhibitors - AJMC

Key Differences Among ALK Inhibitors  AJMC

Key Differences Among ALK Inhibitors - AJMC

Click here to get full coverage on Wall Street Analysts Think Alaska Air (ALK) Is a Good Investment: Is It? - Yahoo Finance

Wall Street Analysts Think Alaska Air (ALK) Is a Good Investment: Is It?  Yahoo Finance

Wall Street Analysts Think Alaska Air (ALK) Is a Good Investment: Is It? - Yahoo Finance

Click here to get full coverage on Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System - CancerNetwork

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System  CancerNetwork

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System - CancerNetwork

Click here to get full coverage on Integrating Lorlatinib Into First-Line ALK-Positive NSCLC Treatment - CancerNetwork

Integrating Lorlatinib Into First-Line ALK-Positive NSCLC Treatment  CancerNetwork

Integrating Lorlatinib Into First-Line ALK-Positive NSCLC Treatment - CancerNetwork

Click here to get full coverage on FDA Approves Ensartinib in ALK-Positive NSCLC - Targeted Oncology

FDA Approves Ensartinib in ALK-Positive NSCLC  Targeted Oncology

FDA Approves Ensartinib in ALK-Positive NSCLC - Targeted Oncology

Click here to get full coverage on New collaborative effort aims to cure ALK-positive lung cancer - News-Medical

New collaborative effort aims to cure ALK-positive lung cancer  News-Medical

New collaborative effort aims to cure ALK-positive lung cancer - News-Medical

Click here to get full coverage on ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States - GlobeNewswire

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States  GlobeNewswire

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States - GlobeNewswire

Click here to get full coverage on Why Insiders Are Selling Alaska Air Group, Inc. (ALK) Recently - Yahoo Finance

Why Insiders Are Selling Alaska Air Group, Inc. (ALK) Recently  Yahoo Finance

Why Insiders Are Selling Alaska Air Group, Inc. (ALK) Recently - Yahoo Finance

Click here to get full coverage on Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLC - CancerNetwork

Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLC  CancerNetwork

Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLC - CancerNetwork

Click here to get full coverage on Why Alaska Air Group (ALK) Outpaced the Stock Market Today - MSN

Why Alaska Air Group (ALK) Outpaced the Stock Market Today  MSN

Why Alaska Air Group (ALK) Outpaced the Stock Market Today - MSN

Click here to get full coverage on Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma | Oncogene - Nature

Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma | Oncogene  Nature

Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma | Oncogene - Nature

Click here to get full coverage on Why Alaska Air Group (ALK) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Why Alaska Air Group (ALK) is a Top Momentum Stock for the Long-Term  Yahoo Finance

Why Alaska Air Group (ALK) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Click here to get full coverage on ALK Announces New AllerTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis - PR Newswire

ALK Announces New AllerTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis  PR Newswire

ALK Announces New AllerTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis - PR Newswire

Click here to get full coverage on Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia | npj Precision Oncology - Nature

Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia | npj Precision Oncology  Nature

Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia | npj Precision Oncology - Nature

Click here to get full coverage on Is Alaska Air Group (ALK) Outperforming Other Transportation Stocks This Year? - Yahoo Finance

Is Alaska Air Group (ALK) Outperforming Other Transportation Stocks This Year?  Yahoo Finance

Is Alaska Air Group (ALK) Outperforming Other Transportation Stocks This Year? - Yahoo Finance

Click here to get full coverage on Ensartinib Receives FDA Approval for ALK-Positive Locally Advanced or Metastatic NSCLC - AJMC

Ensartinib Receives FDA Approval for ALK-Positive Locally Advanced or Metastatic NSCLC  AJMC

Ensartinib Receives FDA Approval for ALK-Positive Locally Advanced or Metastatic NSCLC - AJMC

Click here to get full coverage on Alaska Airlines warns of slower demand as second-quarter profit outlook falls short - CNBC

Alaska Airlines warns of slower demand as second-quarter profit outlook falls short  CNBC

Alaska Airlines warns of slower demand as second-quarter profit outlook falls short - CNBC

Click here to get full coverage on Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics - Frontiers

Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics  Frontiers

Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics - Frontiers

Click here to get full coverage on Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer - Nature

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer  Nature

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer - Nature

Click here to get full coverage on Alaska Air (ALK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Alaska Air (ALK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates  Yahoo Finance

Alaska Air (ALK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Click here to get full coverage on FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Business Wire

FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)  Business Wire

Alaska Air Group Inc (ALK)

Price Chart

Key Statistics

Technicals

About ALK

Latest News

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer - Pharmacy Times

ALK in cancer: from function to therapeutic targeting - Nature

ALK and Lung Cancer - American Lung Association

Advanced Charts

Top Gainers

Top Losers